world
Tratamiento experimental contra cáncer de pulmón eleva supervivencia a 21 meses, según estudio
El Economista
October 24, 2026
via El EconomistaYou're reading one story from Newsaly
Newsaly brings together 60,000+ newspaper articles, 30,000+ podcasts and 10,000+ magazine articles from around the world.
A World Of News, One Window.
Explore Today's News
La combinación de Imdelltra e Imfinzi alcanzó una supervivencia mediana de 21.1 meses, frente a 12.7 meses con la inmunoterapia sola, en un estudio de 563 pacientes
Read the full story
Explore More On Newsaly
Voices (0)
Share a 15-second voice reaction. Voices automatically disappear after 10 days.
Sign in to record a voice on this article.
Be the first to share a voice on this article.